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ABSTRACT
Introduction A diet low in fermentable oligosaccharides,
disaccharides, monosaccharides and polyols (FODMAP)
is an effective way to reduce gut symptoms in people
with irritable bowel syndrome (IBS). This diet reduces the
intake of fermentable fibres, leading to changes of the
gut microbiota and insufficient fermentation in the large
bowel, resulting in reduced production of short-chain fatty
acids (SCFAs), such as butyrate, which has unfavourable
implications for gut health, sleep and mental health. This
study will examine the effect of Fibre-fix, a supplement
containing a mix of dietary fibres, on the human gut
microbiome composition, fermentative capacity, sleep,
quality of life (QOL) and mental health of people with IBS
who consume a low FODMAP diet (LFD).
Methods and analysis A randomised, double-blind,
placebo-controlled, study design is proposed to examine
whether Fibre-fix added to an existing LFD may help
modulate gastrointestinal function, improve markers of
sleep, mental health and promote QOL in patients with
IBS. Participants will provide stool and blood samples,
daily bowel symptoms diaries and 3-day diet records.
Additionally, they will complete validated questionnaires
relating to FODMAP intake, sleep, mental health and QOL
before and after a 3-week intervention. Gut health will
be assessed via faecal microbiome composition, faecal
pH and SCFA levels. Alteration of sleep will be recorded
using an actigraphy device worn by all participants over
the whole study. Multivariate analysis will be used to
examine the gut microbiome and repeated measures
Analysis of variance (ANOVA) will be used for dependent
variables from questionnaires related to bowel symptoms,
stool type, sleep, mental health and QOL to assess the
differences between intervention and control groups after
adjustment for confounding variables.
Ethics and dissemination Ethics approval was obtained
from the Human Research Ethics Committee of Edith
Cowan University (2019-00619-YAN). Results will be
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disseminated in peer-review journal publications, and
conference presentations. Participants will be provided
with a summary of findings once the study is completed.
If Fibre-fix is shown to result in favourable changes in gut
microbial composition, SCFA production, sleep and mental
well-being without exacerbating symptoms, this will
provide additional dietary management options for those
with IBS following an LFD.
Trial registration number ACTRN12620000032954.

INTRODUCTION
Irritable bowel syndrome (IBS) is one of
the most frequently diagnosed functional
gastrointestinal disorders, affecting approximately 11.2% of the global adult population.1 2 Diagnosis of IBS is challenging due
to the subjective nature of digestive symptoms and is currently based on the Rome
IV criteria.3 This functional disorder typically presents with recurrent abdominal
pain with alterations in bowel habits, namely
stool consistency and frequency, coexisting
bloating, flatulence and abdominal distention. The syndrome is subtyped into four
patterns: IBS with predominant constipation or predominant diarrhoea, mixed IBS
and un-subtyped.4 Due to the dominance of
chronic symptoms and frequently present
comorbidities, somatic and psychological,
IBS imposes a heavy burden on individuals
and communities both economically and
socially.5 6 Of those employed, patients with
IBS reported 24.3% absenteeism and 86.8%
presentism, due to their syndrome.7 In two
independent studies it were estimated that
1
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Irritable bowel syndrome

IBS-related absenteeism and presenteeism cost industry
£400–£9008 or to €937–€2108 annually.9
A diet that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)10
alias a low FODMAP diet (LFD), is an effective dietary
intervention for IBS. A blinded and placebo-controlled
trial found that approximately three-quarters of patients
with IBS benefit from an LF.11 The LFD reduces food
(fibre) compounds that are poorly absorbed in the small
intestine, rapidly fermentable in the proximal colon,
and thereby contribute to the gastroenterological symptoms. The LFD includes a selective elimination diet for
2–6 weeks followed by a reintroduction phase of FODMAP
containing foods followed by personalisation of a diet
that minimises symptoms.12 13 Despite the positive effects
of the LFD in reducing gut symptoms and improving
quality of life (QOL) in those with IBS, it only treats the
symptoms of IBS. Studies suggest potentially negative
impacts of long term adherence to an LFD, including
nutritional inadequacy, potential increased risk of gastrointestinal complications and imbalance of the gastrointestinal microbiome.12 14 15 Evidence from both animal
and human studies has demonstrated that a low intake of
dietary fibres can reduce microbiota diversity leading to
increased cancer risk.16–19 Reintroduction or restoration
of dietary fibres to an LFD diet can be difficult with whole
food due to the coexistence of a range of fibres in individual foods. This study therefore reintroduces dietary
fibre using a supplement however this process should
be done gradually and continuous, otherwise unwanted
symptoms such as gas, flatulence and cramps may impact
adherence.
Research suggests a low FODMAP intake rapidly and
negatively changes the gut microbial community, abundance and diversity.15 20 21 In healthy people, a 1-week LFD
resulted in an alteration of the gut microbiota, reduced
beneficial bacteria such as Actinobacteria, predominantly Bifidobacterium, and a lower overall total bacterial
count.22 After a 4-week LFD, Bennet et al23 observed an
increased dysbiosis manifested as altered gut microbial
fermentation leading to lower total short-chain fatty acid
(SCFA) concentrations24 in patients with IBS. Additionally, a randomised, cross-over trial comparing LFD with a
standard Australian diet15 found a marked reduction in
butyrate‐producing Clostridium cluster XIVa and cluster
IV, favourable mucus-associated Akkerkmansia muciniphila,
and an increase in mucus-
detrimental Ruminococcus
torques. In another study, Bifidobacterium and Faecalibacterium prausnitzii associated with butyrate production were
significantly decreased following a 3-week LFD.25 Taken
together these results suggest the lack of fibre associated
with LFD may explain the microbial changes. Human
gut microbiota is able to recognise and degrade different
forms of complex carbohydrate.26–28 A diet rich in
dietary fibres with different extents of fermentability and
solubility is recommended, which means more varied
and complex dietary fibres in the diet leads to a more
dynamic, diverse and stable gut microbiota.29 Various

purified dietary fibres are capable of nourishing specific
gut bacteria, such as Bifidobacteria, F. prausnitzii and Eubacterium hallii.26 30–32 Dietary fibre improves the human gut
microbiota by providing a substrate for fermentation,
and subsequently increases production of SCFA. It is well
established in the literature that higher levels of SCFA can
be obtained from a higher intake of fermentable dietary
fibres.19 33 34 Butyrate, one of the major SCFA throughout
the colon, provides the primary fuel for colonic cells to
maintain growth and integrity and thereby improve gut
health.35–37 Furthermore, research suggests that butyrate
can positively affect circadian rhythm regulation38 39 and
enhance sleep via interplay between gut and brain.40
Therefore, this study will increase the amount of fibre
in the diet of patients with IBS to restore the gut microbiome and its metabolite profile to potentially prevent
increasing the risk of patient’s developing other more
severe gastrointestinal diseases.
Thirty-three per cent of patients with IBS reported they
had sleep problems, such as sleep fragmentation, poor
sleep quality, reduced sleep time and frequent awakening.41 42 Disordered sleep or sleep disturbances are
also recorded with a greater prevalence in IBS sufferers
compared with healthy individuals.43 44 Despite unknown
causal relationship between impacted sleep and IBS, the
close association between gastrointestinal symptoms and
sleep disturbances has been identified by others.45–47 The
gut microbiota is suggested to play a pivotal role and
affect multiple mechanisms in this complex relationship
between human sleep disturbances and gastrointestinal
disease.48 49 Smith et al50 found that gut microbial diversity was positively associated with total sleep time, as well
as sleep efficiency which also were positively correlated
with phyla richness of Bacteroidetes and Firmicutes.
Their findings indicate that an diet intervention represent a promising way to improve sleep by manipulating
the gut microbiota to promote sleep-related phyla and
taxa in the human gut microbiome.50 In addition, it has
been suggested that gut microbial composition could be
altered by sleep fragmentation, resulting in a 50% reduction in Actinobacteria and 20% in Bacteroidetes, but a
20% increase in Firmicutes, which is similar to the microbial profile of obese individuals.51 52
Many research studies have demonstrated the significant association between IBS and mental health, even
though the causation relationship is still unclear. A
meta-analysis of Guillaume Fond et al53 concluded that
patients with IBS were more likely to develop depression
and anxiety than healthy volunteers groups, whereas
Sibelli et al54 found that depression and anxiety doubled
the risk of IBS onset. It is estimated that 44% of patients
with IBS have associated mental health conditions, such
as depression and anxiety.55 Patients with IBS have been
observed with gut microbial alterations related to depression, including greater rates of kynurenine (a deleterious
metabolite of tryptophan), an elevated kynurenine/tryptophan ratio,56 and declined Lactobacillus and Bifidobacterium which are also less abundant in patients with major

2
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depressive disorder.57 Clostridia, a major class within the
phylum Firmicutes, appears at increased abundance in
patients with IBS.58 59 This link to an animal study showing
abundance of Clostridia were significantly higher after
stress-related stimuli in stress-vulnerable rats compared
with stress-resilient rats.60 Demonstrating that gut microbial communities respond to stress differently among
animals with distinct stress vulnerability. Furthermore,
the researchers suggest a Bacilli to Clostridia ratio can
reflect stress effects, with a higher value indicating less
stress-derived inflammatory reactions.60
Some inflammatory markers in human blood are associated with both human gut health and mental health
and provide a potential mechanism for the role of
dietary fibre in mitigating mental health. A randomised
controlled trial in patients with serious depression demonstrated serum concentration of high-sensitivity C reactive
protein (hs-CRP) and scores of Beck Depression Inventory questionnaire significantly decreased after taking a
probiotic supplement (Lactobacillus spp and Bifidobacterium bifidum).61 Additionally, proinflammatory cytokines,
like tumor necrosis factor alpha (TNF-α), interleukin
(IL-6) and IL-1β, are able to cross the blood-brain barrier
(BBB), and their entry and following influences can
have a negative effect on mental health.62 The entry of
the cytokines, however, can be reduced by improving the
integrity of blood brain barrier. The permeability of BBB
can be decreased by the SCFA butyrate which is produced
in the gut via gut bacterial fermentation of fermentable
carbohydrate residue escaping from small intestinal
digestion.63
In summary, a healthier gut microbiota altered by
a dietary fibre intervention or supplement in patients
with IBS may not only improve gut health but also sleep,
mental health and QOL. The objective of this research
study is to determine, in patients with diagnosed IBS and
on an LFD, whether Fibre-fix, compared with a placebo
control, improves gut microbial composition, faecal
SCFA levels, sleep quality, QOL, markers inflammation
and of mental well-being, without exacerbation of IBS
symptoms. This study will be the first to explore the bidirectional relationship between dietary fibres supplement
and sleep modulated by the gut microbiota in patients
with IBS following the LFD.

Figure 1 Flow chart showing study design overview.

was required to detect a change in log SCFA concentration of 0.4 at 80% power and 5% level of significance.
Allowing for a 15% drop-out rate, the total sample size
of 58 subjects, 29 per group is required. This sample
size is sufficient to detect at least a medium between-
within group interaction effect (Cohen’s f=0.25) in sleep
improvement at 80% power and 5% significance level,
whereby the corresponding sample size requirement is
34.

Sample size
The a priori sample size for the proposed study was determined based on the results obtained by McOrist et al,64
where a sample size of 50 participants (25 per group)

Participants
Fifty-eight people (n=58) with IBS on an LFD will be
recruited. Participants must be between 18 and 65 years
old and have been clinically diagnosed with IBS, using the
Rome IV edition diagnostic criteria65 by a gastroenterologist or other medical professional. Participants will be on
an LFD for 1 month prior to the intervention. Additionally, participants will need to be available to attend the
local clinic visits and be willing to consume the Fibre-fix
supplement or matched placebo.
Participants will be excluded if they are current
smokers; pregnant or planning to become pregnant;
have a known diagnosis of other gastrointestinal illness
(eg, inflammatory bowel disease, malabsorption of any
macronutrients, bowel resection, coeliac disease); have
had previous abdominal or gastrointestinal surgeries,
severe mental health and sleep-related conditions (eg,
insomnia), renal or hepatic diseases, and major medical
illness; currently use pharmaceutical agents that could
modify or treat IBS (eg, probiotics, antibiotics, eluxadoline, lubiprostone and linaclotide) or sleep conditions;
follow other restrictive dietary patterns or therapies (eg,
low-carbohydrate, keto/Paleo-diet); take any prebiotics;
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METHODS AND ANALYSIS
Study design
The study is designed as a randomised, double-blinded,
placebo-
controlled trial, with a 3-
week intervention
period (figure 1). The total time required for participant
involvement is 4 weeks, including a 1-week baseline and a
3-week intervention.
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have any other disease, condition or habit that may interfere with completion of study.

sheet. All stool samples collected with the 24 hours
period will be pooled and homogenised if the number
of individual samples is more than one. On receipt, stool
samples will be immediately weighed and stored at −80°C.
Individual’s samples will be thawed at 4°C and kept at this
temperature during homogenised and aliquoting for all
planned analysis and re-frozen at −80°C until analyses.
The concentrations of bacterial metabolites in faeces,
such as SCFA (acetate, propionate and butyrate) will be
determined by gas chromatography.66 In brief, an acidified aqueous methanol solution will be used to extract
SCFA from faecal samples, followed by separating SCFA
by gas chromatography with a fatty acid column using a
Thermo Scientific TG-Wax column(30 m x 0.25 mm x
0.25 μm). The SCFA level will be qualified via internal
standards.
Microbial analyses will be performed at the WA Human
Microbiome Collaboration Centre, Curtin University,
Western Australia. DNA will be extracted using the
QIAamp PowerFecal DNA kit (Qiagen) using Qiacube
extraction platform. Microbiome signatures are generated using the Illumina MiSeq platform using uniquely
barcoded 16S rRNA gene primers (515-806(V4)) for
bacterial and ITS2 primers for fungal profiling (pending
on funding), following PCR inhibition assessment of each
DNA extract. PCR-
free ligation protocol is thereafter
deployed for the process of library building. Samples
will be sequenced to a depth of minimum 50 000 reads,
which is sufficient to identify microbes to a genus/species
level. Quality control and mock community samples
are included in the analysis from sample collection
to sequence analysis. Sequence read quality is initially
assessed with FastQC before demultiplexing and preprocessing by GHAPv2, an in-house tool. Cutadapt67 is used
for removal of all non-biological sequences. DADA268 is
then used for quality filtering, error correction, amplicon
sequence variants (ASVs) picking. A trained naïve bayes
classifier then assigns ASVs to genus/species against a
curated database of microbial reference sequences such
as the Ribosomal Database Project (RDP)69 or Genome
Taxonomy Database.70 For fungal classification the
UNITE database71 will be used.

Recruitment
Participants will be recruited through networks of registered Western Australian based dietitians and gastroenterologists who will be provided with information flyers to
promote the study to potential participants. Information
flyers will be posted on websites including social media
groups relating to IBS or FODMAP. A university webpage
will advertise study information.
Allocation, blinding and compliance
A computer-generated list of random numbers provided
by a statistician will be used to randomly assign participants to either the intervention or control group. The
participants will receive a resealable snap-
lock bag,
labelled A or B, containing 40 sachets of either Fibre-fix
or placebo. Both participant and researcher will be
blinded from the group allocation. Bag labelling will be
completed by an independent person. The participants
will be required to return unused sachets to calculate
compliance. An online daily checklist, together with a
weekly text/email reminder, will be provided to participants to record time of consuming the intervention; a
daily tick-list/calendar will be created for participants to
follow. Consumption of >80% of the sachets (32 sachets)
during the 3-week period will be considered compliant.
Intervention
Fibre-fix consists of one soluble dietary fibre and one
insoluble fermentable fibre, which will be provided
to participants in 40 separate sachets with gradually
increasing amount (table 1). After baseline data collection, participants will be required to consume Fibre-fix as
per the labels on the sachets, one sachet per day for the
first 2 days and two for the remaining 19 days according
to the schedule (table 1). For participants’ convenience,
all sachets have been labelled with day and time (AM or
PM) on the package, for example DAY 3 AM, and will be
provided orderly in resealable plastic bags. The placebo
sachet contains a combination of the same soluble dietary
fibre and highly digestible fibre and will be delivered in
the same way as the intervention.

Secondary outcomes
Objective measures of sleep
Participants will be provided with the Readiband V.5
(Readiband, Fatigue Science, Canada), a wrist-
activity
monitor that has been validated and objectively assesses
sleep using accelerometery.72 Compared against polysomnography—the gold standard of sleep measurement, the
wrist-activity monitor does not require laboratory setup

Primary outcomes
Faecal SCFA and gut microbiota
Faecal SCFA levels and gut microbiota will be assessed
through 24 hours stool samples which will be obtained at
baseline and at the end of the intervention. Participants
will be provided with the stool collection kit, including a
portable cooler bag, frozen icepacks and an instruction

Table 1 Grams of dietary fibre supplement in each sachet provided to participants during 3-week interventional period
Day

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

AM
PM

5
\

5
\

5
5

5
5

10
10

10
10

10
10

20
10

20
10

20
10

20
20

20
20

20
20

20
20

20
20

20
20

20
20

20
20

20
20

20
20

20
20
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Table 2 Definitions of sleep measures as extracted from the Readiband (Fatigue Science, Canada) device, based on Dunican
et al72
Sleep measures

Acronym

Units

Abbreviated

Measurement

Description

Time at Lights Out

TALO

Time of day

hh:mm

Sleep Onset Latency

SOL

Minutes

min

Directly
measured
Derived

Time at Sleep Onset minus Sleep Onset
Latency.
Number of minutes from Time at Lights
Out to Time at Sleep Onset.

Time at Sleep Onset

TASO

Time of day

hh:mm

Directly
measured

Time of day when the first epoch of sleep
occurs between Time at Lights Out and
Time at Wake.

Time at Sleep Onset
Variance

TASOV

Minutes

min

Derived

Time at Sleep Onset consistency relative
to mean Time at Sleep Onset.

Sleep Duration

SD

Minutes

min

Derived

Number of minutes from Time at Sleep
Onset to Time at Wake, minus number of
minutes awake (WASO).

Wake After Sleep
Onset

WASO

Minutes

min

Directly
measured

Number of minutes awake after Time at
Sleep Onset.

Fragmentation Index

FI

Frequency

number

Directly
measured

Number of awakenings between Time at
Sleep Onset and Time at Wake.

Time at Wake

TAW

Time of day

hh:mm

Directly
measured

Time of day when awake with no further
Sleep Duration.

Time in Bed

TIB

Minutes

min

Derived

Sleep Efficiency

SE

Percentage

%

Derived

The total time spent in bed, from Time at
Lights Out to Time at Wake.
Sleep Duration divided by Time in Bed
multiplied by 100.

nor trained personnel.72 Moreover, the Readiband can
automatically identify time at lights out using a proprietary algorithm, which not only eases the burden of sleep
diary but also avoids the potential bias from self-reported
data of recalling time for bed.72 This technology has been
widely applied to the sleep-related research.73–76 Participants will be required to wear the monitor on the non-
dominant wrist for 24 hours per day during the study. The
monitor-derived sleep measure data will be downloaded
via the automated Readiband Sync software (table 2).
Subjective measures of sleep
Participants will be required to complete five validated
questionnaires related to sleep at baseline, and at the end
of the intervention.
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) retrospectively assesses sleep quality and relevant disturbances over
the previous month. This self-
administrated questionnaire has been validated in a population-based setting to
measure sleep quality. The summary score is calculated
as the summation of 19 items grouped into seven components, ranging from 0 (better) to 21 (worse); a score >5
indicates poor sleep quality.77

chance of dozing) to 3 (would never doze), which yield a
global score of ESS ranging from 0 to 24. Scores higher
than nine reflect excessive daytime sleepiness and severe
problems with daytime somnolence.79
Insomnia Severity Index
Insomnia will be assessed through the self-
reported
Insomnia Severity Index (ISI) comprising seven items.
Participants are required to rate each question on a
5-point Likert scale as per their own experience over
the past 2 weeks. The total score ranges from 0 to 28,
and represents clinical insomnia when it is higher than
14.80
Sleep Hygiene Index
The Sleep Hygiene Index (SHI) is a self-reported instrument for assessing individual behaviours in sleep hygiene.
The 13 items that comprise SHI are rated on a 5-point
Likert scale and produce a total score ranging from 0 to
52 with higher scores representing poorer status of sleep-
behavioural hygiene.81

Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) is a self-rated eight-
item questionnaire, designed to measure daytime sleepiness.78 Participants score each question from 0 (high

Restorative Sleep Questionnaire weekly version
The Restorative Sleep Questionnaire weekly version
(RSQ-w) is composed of nine questions completed on
restorative aspects of the sleep during the past week, and
whose reliability and validity has been published.82 Each
item scales from one to five. The first two items and the
last item are reversed scored. The total score ranging
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from 0 to 100, calculates as: (RSQ-w average score across
completed items−1)×25. The higher total scores indicate
better restorative sleep.
Mental health and QOL assessment
The condition of mental health and QOL in both groups
will be assessed using in total four validated questionnaires at baseline and at the end of the intervention.
Depression Anxiety Stress Scale
The Depression Anxiety Stress Scale (DASS-21) is a validated self-reported questionnaire designed to measure
three subscales which are depression, anxiety and stress
with seven items for each dimension.83 Higher scores
are indicative of poorer mental condition and severity of
symptoms, but the DASS-21 is not a clinically diagnostic
instrument. Nonetheless, DASS-21 has broad applicability and free availability and has been validated among
the general population and for patients with chronic
disease.84 85
Scores above 14, 10 and 17 in the three dimensions
indicate severe depression, anxiety and stress, respectively. In such instances, participants will be referred to
their medical practitioner for clinical care.
Visceral Sensitivity Index
The Visceral Sensitivity Index (VSI) is a validated self-
reported questionnaire and will be employed to measure
gastrointestinal specific anxiety. The total VSI score is
generated from all 15 items, each defined on a 6-point
Likert scale. Patients with a higher score will be regarded
as experiencing severe gastrointestinal symptom-specific
anxiety.86 87
IBS Quality of Life
For assessment of participants’ QOL, IBS-QOL questionnaire will be used at the stages of baseline clinic, prior
to and after intervention. The IBS-
specific questionnaire is a validated measurement tool, generating one
total and eight subscale scores with 34 items covering
dysphoria, interference with activity, body image, health
worry, food avoidance, social reaction, sexual activity and
relationships.88
WHO (Five) Well-Being Index
WHO (Five) Well-Being Index (WHO-5) is a validated
self-
reported questionnaire consisting of five items
that measures mental well-being in relation to the past
2 weeks. Responders rate each item on a 6-point Likert
scale. The result will be calculated by multiplying the raw
total score, ranging from 0 to 25, by four. The higher
scores represent those with a better imaginable well-being
condition.89
All questionnaires will be collated in the software
Qualtrics and administered online to reduce participant
burden.

6

Demographic information
Participants will complete a demographic questionnaire
which requires personal information: gender, age, nationality, marital status, area of residence, mobile number,
email address, smoking history, alcohol consumption,
birth delivery mode, dietary pattern and physical activity.
Anthropometric measurements
Participants’ height (cm) and weight (kg) will be
measured to the nearest 0.1 cm and 0.1 kg, respectively,
by an SECA 763 digital column scale (SECA, USA), where
circumferences of waist and hips will be measured in
accordance with international operating procedures for
anthropometric assessment.90 Body mass index (BMI)
and waist/hip ratio will be calculated.91 Percentage of
lean and fat mass will be obtained using the BOD POD
(Cosmed, Rome, Italy), an Air Displacement Plethysmograph using whole body densitometry, to determine body
composition (fat vs lean % fat mass),92 and conducted
following manufacturer protocols for measurement. This
will require subjects to fast for 8 hours prior to testing and
wear tightly fitted gym clothes for measurement. Blood
pressure (mm Hg) will be measured using an Omron
IA1B Automated Blood Pressure Device (Omron Healthcare, Japan). All measurements will be carried out at
baseline and end of intervention.
Blood biomarkers
The venous blood samples will be collected after an overnight fast at baseline and at the end of the intervention.
Blood samples will be centrifuged and processed within
half an hour after collection for separating plasma and
serum, and frozen at −80°C after being aliquoted into
2 mL vials. Analysis of fasting lipids, glucose and glycated
haemoglobin will be performed by a pathology laboratory in accordance with the protocols from the National
Association of Testing Laboratories. The outcome
measures of hs-CRP, TNF-α, IL-6 and IL-1β will be analysed if funding is made available.
Gut symptoms
Participants will complete a bowel symptom questionnaire at baseline and postintervention to assess changes in
symptom severity. The questionnaire consists of Gastrointestinal Symptom Rating Scale for IBS (GSRS-IBS)93 and
the IBS Severity Scoring System (IBS-SSS),94 which have
been validated in clinical trials. The 13-item GSRS-IBS
uses a 7-point Likert scale for severity of symptoms characteristic of IBS including abdominal pain, diarrhoea,
constipation and bloating satiety. This instrument is short
and simple, and will assist researchers to determine the
specific symptoms encountered by patients.93 The IBS-
SSS point, with a maximum of 500 (100 for each item), is
also used for classification of patients as remission (<75),
mild (75–175), moderate (176–300) or severe (>300).
Participants will use a visual analogue scale to score each
of the five questions regarding symptom severity which
include pain severity and duration, abdominal distention,
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bowel dysfunction and QOL. For this study, a reduction
of more than 50 points of IBS-SSS is defined as symptoms
improvement.13
Daily Symptoms checklist
Each participant will be provided with an online daily
bowel symptom checklist to report the sachet-consuming
time and daily symptoms throughout the entire study
period (Adapted from the not for profit, International
Foundation for Functional Gastrointestinal Disorders
(IFFGD) Personal Daily Diary: https://
aboutibs.
org/
symptom-
diary.
html). The checkbox items include
Bristol stool chart type, time and amount of fibre added
to meals, bowel movement number of motions, stress
level and menstrual cycle. Adverse symptoms monitoring,
scoring symptoms (0–10), will be reported by participants daily and include abdominal pain, constipation,
diarrhoea, bloating, flatus, eructation, headache, nausea
and vomiting.
Food records
Dietary intake will be assessed using a 3-day weighed
food record preintervention and postintervention. This
will be completed by participants via a free downloaded
smart-phone application, Research Food Diary (Xyris,
Queensland, Australia). Participants will be provided
with a set of scales (Propert, Supertex Industries)

and instructed on the correct recording methods for
weighed diet records. The Monash University Comprehensive Nutrition Assessment Questionnaire will be
used to specifically quantify individuals’ FODMAP
intake.
Table 3 schedule of primary and secondary endpoints
that will be measured over the study.
Statistical analyses
Baseline participant demographics and primary and
secondary outcome variables will be described and
compared for differences by group. Descriptive statistics
in the form of mean±SD will be used to describe continuous variables, and frequencies and proportions for
nominal and ordinal variables. All continuous outcome
and demographic variables will be examined normality
using the Shapiro-Wilk test. Median±IQR range will be
presented instead for non-normal continuous variables.
Change in individual and total SCFA levels and faecal
pH, will be examined using mixed-
model Analysis of
variance (ANOVA) between-groups and within-groups.
Covariates, including gender and age, will be entered
into the model as confounders. To analyse the gut
microbiota profiles, multivariate analysis, Primer7 and
PERMANOVA+ (PRIMER-
E, Plymouth) and various R
packages, will be used. Principal coordinates analysis
will be deployed to visualise data. Distance-based linear

Table 3 Study assessment schedule
3-week dietary intervention

Study item

Baseline
period

W1

W2

W3

Post-intervention

Demographic information

✓

 

 

 

 

BMI, body fat, waist/hip ratio

✓

 

 

 

✓

Gut symptoms questionnaire (IBS-SSS+GSRS IBS) ✓

 

 

 

✓

Pittsburgh Sleep Quality Index

 

 

✓

✓

 

Epworth Sleepiness Scale

✓

 

 

 

✓

Sleep Hygiene Index

✓

 

 

 

✓

Insomnia Severity Index

✓

 

 

 

✓

Restorative Sleep Questionnaire weekly version

✓

 

 

 

✓

Depression Anxiety Stress Scale

✓

 

 

 

✓

Visceral Sensitivity Index

✓

✓

 

 

 

IBS-Quality of Life

✓

 

 

 

✓

WHO (Five) Well-Being Index

✓

 

 

 

✓

Monash University: Comprehensive Nutrition
Assessment Questionnaire

✓

 

 

 

✓

Blood sample

✓

 

 

 

✓

Stool sample

✓

 

 

 

✓

Three-day diet record (via research food diary)

✓

 

 

 
✓

 

Sleep monitor—Readiband wrist wearable device

✓

✓

✓

✓

 

Daily symptoms checklist

 
✓

✓

✓

✓

 

BMI, body mass index; GSRS-IBS, Gastrointestinal Symptom Rating Scale for irritable bowel syndrome; IBS-SSS, irritable bowel syndrome
Severity Scoring System.
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models and distance-based redundancy analysis will be
used to integrate microbiome findings with clinical, diet
intake, immune function and other relevant data that
might help explain the relationship between the microbiome findings and other outcomes. If a significant relationship or difference is established at the multivariate
level, multiple linear regression (MLR) will be conducted
at the univariate level to determine the association
between the gut microbiota composition and SCFA levels,
faecal pH, diet intake, sleep, mental health. The covariates including gender, age, intervention compliance and
IBS subtype will be considered as confounding variables
and are adjusted in the MLR modelling. False discovery
rate correction will be applied to account for testing of
multiple outcomes.
For the effect of Fibre-fix on IBS symptomology, dependent variables (DV) from the Bristol Stool Chart type and
symptom severity scores collected from daily symptom
checklist will be examined by group. Differences
between-
groups and within-
groups in these outcomes
will be assessed using mixed-model repeated measures
ANOVA, adjusting for sex and age. The DV from the
questionnaires for sleep, mental health and QOL include
PSQI, ESS, ISI, SHI, RSQ-w, DASS-21, VSI, IBS-QOF and
WHO-5 will be analysed in the same way as mentioned
above.
All data analyses, other than the microbiome multivariate data, will be conducted using SPSS V.25.0.95 Significance level is set at p≤0.05. Cohen’s effect size will be
presented, where appropriate, to provide a measure practical/clinical significance.

DISCUSSION
The double-blinded, randomised controlled trial aims to
examine whether Fibre-fix, in patients with IBS following
an LFD, can improve gut microbiome composition, faecal
SCFA concentrations, sleep quality, QOL and mental
well-being, without exacerbation of IBS symptoms. Negative impacts on the gut microbiota of the LFD have been
emerging, despite positive effects on IBS symptoms
control.12 Therefore, how to maintain a low level of IBS
symptoms and concurrently improve the gut microbiome
requires further research. Fibre-
fix, a combination of
fibres, may improve gut health of IBS subjects through
greater distal fermentation in the colon. This combination
may avoid triggering IBS symptoms, promote gut fermentation and SCFA (particularly butyrate) production which
increases the biosynthesis and metabolism of neurotransmitters that could improve sleep and mental conditions. If
Fibre-fix can improve the gut microbiota as expected, this
will propose a long-term dietary solution for those with IBS.
The proposed mental health and sleep benefits may have a
flow-on effect in terms of lowering the occurrence of other
comorbidities, such as depression, anxiety and work absenteeism, which have economic benefits. In addition, if the
cost-effective dietary fibre administration is well-tolerated,
it may also significantly lower the economic and mental
8

burden originating from IBS comorbidities on patients,
the healthcare system as well as the wider community.
Limitations
This is the first study to assess the effects of Fibre-fix on
patients with IBS and as a result there are limitations
which broadly include: time, funding and participants’
burden. Specifically, this study will not explore hormonal
changes relating to melatonin and serotonin caused by
the dietary fibre supplement which may be helpful to
further understand the mechanism and association of
gut-brain axis. Moreover, the long-term effects of dietary
fibre supplement will not be determined in this study
because the study period is four weeks (1-week baseline
and 3-week intervention). The gut microbiome and its
metabolite profile (SCFA) are primary outcomes in this
study as they will be valuable predictors of an improved
gut health because of the reactive nature of the gut
microbiome to diet changes. Therefore, such changes
can be used to predict the value of Fibre-fix in lowering
the risk of more severe gastrointestinal diseases in the
future, but such findings would need to be validated in a
long-term study. For sleep assessment, this study does not
apply polysomnography. Therefore, changes in specific
sleep stages will not be available, despite abnormality in
rapid-eye movement among patients with IBS has been
reported.96 Future studies would therefore be required
to explore the long-term and mechanistic relationship
between human gut health, diet, sleep and mental health.
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